What is Innogenix?
Innogenix is a pharmaceutical company dedicated to the development and manufacturing of generic medications. Its core mission is to enhance healthcare accessibility by providing cost-effective and reliable medication alternatives to a broad spectrum of clients, including pharmacies, hospitals, and healthcare providers. The company's extensive product catalog spans various therapeutic areas, ensuring it can address diverse patient needs. Innogenix operates with a strong commitment to quality assurance and regulatory compliance, aiming to improve patient outcomes through its high-standard generic drug offerings.
How much funding has Innogenix raised?
Innogenix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Innogenix
PPP
Public-Private Partnership
What's next for Innogenix?
The substantial late-stage funding Innogenix has attracted signals a pivotal moment for the company, likely enabling significant expansion of its manufacturing capabilities, research and development initiatives, and market penetration. This strategic investment is expected to fuel the company's growth trajectory, potentially leading to the introduction of new generic formulations and the strengthening of its position in the competitive pharmaceutical landscape. Innogenix is poised to further solidify its role in making essential medications more affordable and accessible.
See full Innogenix company page
